News tagged with avastin
U.S. health officials are making a high-tech screening device available to African authorities to help spot counterfeit malaria pills in hopes that the technology may eventually be used to combat the fake drug trade worldwide.
Medications Apr 24, 2013 | not rated yet | 0
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
Cancer Apr 19, 2013 | 5 / 5 (2) | 0 |
(HealthDay)—Monica Barlow, a 35-year-old from Maryland, was training for a half-marathon when she noticed she couldn't shake a bad cough and ongoing fatigue. After a couple of rounds of antibiotics from ...
Cancer Apr 18, 2013 | not rated yet | 0
(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.
Medications Mar 21, 2013 | not rated yet | 0
(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.
Medications Mar 20, 2013 | not rated yet | 0
The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain ...
Cancer Feb 14, 2013 | not rated yet | 0
(HealthDay)—Aiming to reduce the global threat of counterfeit drugs, a new Institute of Medicine report also recommends changes in the United States that include a mandatory drug-tracking system and tighter ...
Medications Feb 13, 2013 | not rated yet | 0
(AP)—A new report calls for a national drug tracking system to fight the growing problem of fake drugs.
Medications Feb 13, 2013 | not rated yet | 0
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts ...
Ophthalmology Feb 12, 2013 | not rated yet | 0
Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer
(Medical Xpress)—Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not ...
Cancer Feb 08, 2013 | not rated yet | 0
The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year.
Medications Feb 06, 2013 | 5 / 5 (1) | 0
Growing demand for its cancer medicines and diagnostic tests used by clinical laboratories helped Swiss drug maker Roche Holding AG post a modest 2.4 percent increase in full-year profits.
Other Jan 30, 2013 | not rated yet | 0
(HealthDay News) —For advanced colon cancer patients who have developed liver tumors, so-called "radioactive beads" implanted near these tumors may extend survival nearly a year longer than among patients ...
Cancer Jan 21, 2013 | not rated yet | 0 |
(HealthDay)—The drug Avastin (bevacizumab), when added to chemotherapy, does not improve disease-free survival in patients with triple-negative breast cancer any better than chemo alone, new research finds.
Medications Dec 07, 2012 | not rated yet | 0 |
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, ...
Cancer Nov 01, 2012 | not rated yet | 0
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.